Progress report IV on AIDS vaccine in human: phase I clinical trial in HIV infected patients.
Int Conf AIDS 1991 Jun 16-21; 7:39 (abstract no. M.A.67) Zagury D, Picard O, Halbreich A, Bernard J, Carelli C, Bizinni B, Salaun JJ, Lurhuma Z, Mbayo K, Burny A, et al; Universite Pierre et Marie Curie, Paris, France
Vaccine trial phase I performed in AIDS patients, using autologous cells expressing HIV1 antigens was performed at the University Clinic of Kinshasa and at Hospital Saint Antoine. Clinical and biological benefit was observed(a,b), but no repair of specific cellular immunity was apparent as if 1) the benefit was due to restoration of natural immunity, the breakdown of which is responsible of opportunistic infections and 2) a peripheral immune suppression was blocking all specific immune reactions. The latter defect prompted us to evaluate whether antisuppressive immunization including fixed autologous suppressive cells would repair specific cellular immunity against multiple antigens. Preliminary clinical trial phase I done on 6 volunteers under vaccinetherapy showed that adding antisuppressive immunization to the ongoing vaccine cure done every 10-12 weeks (2) provided after over one year, an immune improvement as detected by T4 cell count and some cell mediated immunity restoration. In addition, this modified treatment did generate neither immediate side effect nor clinical complication. (a)Mbayo K. et al., Ve Conference sur le SIDA en Afrique, Kinshasa, 1990: (b)Picard O., et al., Lancet 336:179. 1990.
Keywords: AEGIS, AIDS Vaccines, HIV, Clinical Trials, Acquired Immunodeficiency Syndrome, HIV Infections, HIV Antibodies, HIV Antigens, CD4-Positive T-Lymphocytes, HIV Envelope Protein gp160, HIV Envelope Protein gp120, HIV Core Protein p24, Immunization, Immunity, Cellular, HIV Long-Term Survivors, Anti-HIV Agents, Democratic Republic of the Congo, Human, pathogenicity, immunology, ICA7
910616
MA67
